Basic scientific research efforts are aimed at improving the understanding of the activity of immune checkpoint inhibitors in classical Hodgkin lymphoma (cHL). At ISHL 2022, Paczkowska et al. presented results regarding peripheral immune responses to PD-1 blockade that were generated using single-cell RNA sequencing.
Immune-checkpoint blockade plays a key role in the therapeutic landscape of relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, novel strategies to enhance responses remain of clinical interest. In the second-line setting, the phase II study presented by Moskowitz et al. at ISHL 2022 evaluated pembrolizumab in addition to up to four cycles of gemcitabine, vinorelbine, and liposomal doxorubicin (GVD).
The International Symposium on Hodgkin Lymphoma (ISHL) that was organized by the German Hodgkin Study Group (GHSG) and held in Cologne, Germany, and virtually from 22nd–24th October 2022 covered relevant aspects of Hodgkin’s lymphoma research as well as updates on current treatment strategies.
